Improving HbA1c Control in Type 1 or Type 2 Diabetes Using Flash Glucose Monitoring: A Retrospective Observational Analysis in Two ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-12-11

AUTHORS

Ludger Rose, Gerhard Klausmann, Alexander Seibold

ABSTRACT

IntroductionThe aim of this study was to evaluate change in laboratory-measured HbA1c in patients with either type 1 diabetes (T1D) or type 2 diabetes (T2D) on insulin therapy following initiation of the FreeStyle Libre™ flash glucose monitoring system.MethodsThis was a retrospective observational study on adults with T1D or T2D on insulin, who were started on the FreeStyle Libre system as part of standard care. HbA1c was recorded at initiation and at 3-month intervals thereafter.ResultsThe analysis included 131 patients with T1D and 176 patients with T2D on insulin. Mean HbA1c decreased significantly by 3 months following initiation of the FreeStyle Libre system, both in T1D (− 0.75%, p < 0.001) and in T2D (− 0.54%, p < 0.001). Reductions were maintained for 12 months. Change from 3 to 12 months was not significant either in T1D or T2D. Subgroup analysis showed significant reduction in patients with a baseline HbA1c > 7.5–10%, both in T1D (− 0.59%, p < 0.001) and in T2D on insulin (− 0.62%, p < 0.005) at 12 months. Reductions for subjects with HbA1c > 10% were − 4.66% in T1D and − 3.73% in T2D. No change was seen for subjects with a baseline HbA1c ≤ 7.5% (58 mmol/mol). Linear regression confirms that baseline HbA1c is strongly negatively correlated with subsequent change in HbA1c in T1D and in T2D.ConclusionsPatients with T1D or T2D show a reduction in HbA1c by 3 months following initiation of the FreeStyle Libre system. The mean fall in HbA1c at 3 months is strongly negatively correlated with starting HbA1c. This reduction is maintained over 12 months. The significant benefit is seen in patients with a starting HbA1c > 7.5% (58 mmol/mol). More... »

PAGES

363-372

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-020-00978-9

DOI

http://dx.doi.org/10.1007/s13300-020-00978-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1133442360

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/33314006


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Zentrum f\u00fcr Diabetes und Gef\u00e4\u00dferkrankungen M\u00fcnster, Munster, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Zentrum f\u00fcr Diabetes und Gef\u00e4\u00dferkrankungen M\u00fcnster, Munster, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rose", 
        "givenName": "Ludger", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gemeinschaftspraxis Drs. Klausmann, Aschaffenburg, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Gemeinschaftspraxis Drs. Klausmann, Aschaffenburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Klausmann", 
        "givenName": "Gerhard", 
        "id": "sg:person.013245653415.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013245653415.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Abbott Diabetes Care, Wiesbaden, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Abbott Diabetes Care, Wiesbaden, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Seibold", 
        "givenName": "Alexander", 
        "id": "sg:person.015373573342.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015373573342.27"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00125-012-2708-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036534764", 
          "https://doi.org/10.1007/s00125-012-2708-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-019-4894-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1116997264", 
          "https://doi.org/10.1007/s00125-019-4894-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-019-00720-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1122231011", 
          "https://doi.org/10.1007/s13300-019-00720-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-019-00741-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1123313019", 
          "https://doi.org/10.1007/s13300-019-00741-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-016-0223-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024814077", 
          "https://doi.org/10.1007/s13300-016-0223-6"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-12-11", 
    "datePublishedReg": "2020-12-11", 
    "description": "IntroductionThe aim of this study was to evaluate change in laboratory-measured HbA1c in patients with either type\u00a01 diabetes (T1D) or type\u00a02 diabetes (T2D) on insulin therapy following initiation of the FreeStyle Libre\u2122 flash glucose monitoring system.MethodsThis was a retrospective observational study on adults with T1D or T2D on insulin, who were started on the FreeStyle Libre system as part of standard care. HbA1c was recorded at initiation and at 3-month intervals thereafter.ResultsThe analysis included 131 patients with T1D and 176 patients with T2D on insulin. Mean HbA1c decreased significantly by 3\u00a0months following initiation of the FreeStyle Libre system, both in T1D (\u2212\u00a00.75%, p\u2009<\u20090.001) and in T2D (\u2212\u00a00.54%, p\u2009<\u20090.001). Reductions were maintained for 12\u00a0months. Change from 3 to 12\u00a0months was not significant either in T1D or T2D. Subgroup analysis showed significant reduction in patients with a baseline HbA1c\u2009>\u20097.5\u201310%, both in T1D (\u2212\u00a00.59%, p\u2009<\u20090.001) and in T2D on insulin (\u2212\u00a00.62%, p\u2009<\u20090.005) at 12\u00a0months. Reductions for subjects with HbA1c\u2009>\u200910% were \u2212\u00a04.66% in T1D and \u2212\u00a03.73% in T2D. No change was seen for subjects with a baseline HbA1c\u2009\u2264\u20097.5% (58\u00a0mmol/mol). Linear regression confirms that baseline HbA1c is strongly negatively correlated with subsequent change in HbA1c in T1D and in T2D.ConclusionsPatients with T1D or T2D show a reduction in HbA1c by 3\u00a0months following initiation of the FreeStyle Libre system. The mean fall in HbA1c at 3\u00a0months is strongly negatively correlated with starting HbA1c. This reduction is maintained over 12\u00a0months. The significant benefit is seen in patients with a starting HbA1c\u2009>\u20097.5% (58\u00a0mmol/mol).", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-020-00978-9", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "keywords": [
      "FreeStyle Libre system", 
      "baseline HbA1c", 
      "laboratory-measured HbA1c", 
      "flash glucose monitoring system", 
      "retrospective observational study", 
      "retrospective observational analysis", 
      "flash glucose monitoring", 
      "mean HbA1c", 
      "standard care", 
      "insulin therapy", 
      "glucose monitoring system", 
      "mean fall", 
      "subgroup analysis", 
      "IntroductionThe aim", 
      "HbA1c", 
      "observational study", 
      "T1D", 
      "T2D", 
      "patients", 
      "type 2", 
      "German centers", 
      "type 1", 
      "glucose monitoring", 
      "FreeStyle Libre", 
      "months", 
      "insulin", 
      "T2D.", 
      "diabetes", 
      "significant reduction", 
      "observational analysis", 
      "significant benefits", 
      "initiation", 
      "subjects", 
      "linear regression", 
      "MethodsThis", 
      "subsequent changes", 
      "therapy", 
      "care", 
      "reduction", 
      "adults", 
      "study", 
      "changes", 
      "regression", 
      "aim", 
      "fall", 
      "interval", 
      "control", 
      "center", 
      "analysis", 
      "benefits", 
      "monitoring", 
      "types", 
      "system", 
      "part", 
      "monitoring system", 
      "Libre"
    ], 
    "name": "Improving HbA1c Control in Type 1 or Type 2 Diabetes Using Flash Glucose Monitoring: A Retrospective Observational Analysis in Two German Centres", 
    "pagination": "363-372", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1133442360"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-020-00978-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "33314006"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-020-00978-9", 
      "https://app.dimensions.ai/details/publication/pub.1133442360"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:48", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_871.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-020-00978-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-020-00978-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-020-00978-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-020-00978-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-020-00978-9'


 

This table displays all metadata directly associated to this object as RDF triples.

154 TRIPLES      21 PREDICATES      86 URIs      73 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-020-00978-9 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N2326bdfca0034c2a87ff3892a3b97131
4 schema:citation sg:pub.10.1007/s00125-012-2708-9
5 sg:pub.10.1007/s00125-019-4894-1
6 sg:pub.10.1007/s13300-016-0223-6
7 sg:pub.10.1007/s13300-019-00720-0
8 sg:pub.10.1007/s13300-019-00741-9
9 schema:datePublished 2020-12-11
10 schema:datePublishedReg 2020-12-11
11 schema:description IntroductionThe aim of this study was to evaluate change in laboratory-measured HbA1c in patients with either type 1 diabetes (T1D) or type 2 diabetes (T2D) on insulin therapy following initiation of the FreeStyle Libre™ flash glucose monitoring system.MethodsThis was a retrospective observational study on adults with T1D or T2D on insulin, who were started on the FreeStyle Libre system as part of standard care. HbA1c was recorded at initiation and at 3-month intervals thereafter.ResultsThe analysis included 131 patients with T1D and 176 patients with T2D on insulin. Mean HbA1c decreased significantly by 3 months following initiation of the FreeStyle Libre system, both in T1D (− 0.75%, p < 0.001) and in T2D (− 0.54%, p < 0.001). Reductions were maintained for 12 months. Change from 3 to 12 months was not significant either in T1D or T2D. Subgroup analysis showed significant reduction in patients with a baseline HbA1c > 7.5–10%, both in T1D (− 0.59%, p < 0.001) and in T2D on insulin (− 0.62%, p < 0.005) at 12 months. Reductions for subjects with HbA1c > 10% were − 4.66% in T1D and − 3.73% in T2D. No change was seen for subjects with a baseline HbA1c ≤ 7.5% (58 mmol/mol). Linear regression confirms that baseline HbA1c is strongly negatively correlated with subsequent change in HbA1c in T1D and in T2D.ConclusionsPatients with T1D or T2D show a reduction in HbA1c by 3 months following initiation of the FreeStyle Libre system. The mean fall in HbA1c at 3 months is strongly negatively correlated with starting HbA1c. This reduction is maintained over 12 months. The significant benefit is seen in patients with a starting HbA1c > 7.5% (58 mmol/mol).
12 schema:genre article
13 schema:isAccessibleForFree true
14 schema:isPartOf N0eb04d85dadc4afd9ff4553719c0a5c4
15 N5228da9638e1431fb73ce51141eb8dd0
16 sg:journal.1044057
17 schema:keywords FreeStyle Libre
18 FreeStyle Libre system
19 German centers
20 HbA1c
21 IntroductionThe aim
22 Libre
23 MethodsThis
24 T1D
25 T2D
26 T2D.
27 adults
28 aim
29 analysis
30 baseline HbA1c
31 benefits
32 care
33 center
34 changes
35 control
36 diabetes
37 fall
38 flash glucose monitoring
39 flash glucose monitoring system
40 glucose monitoring
41 glucose monitoring system
42 initiation
43 insulin
44 insulin therapy
45 interval
46 laboratory-measured HbA1c
47 linear regression
48 mean HbA1c
49 mean fall
50 monitoring
51 monitoring system
52 months
53 observational analysis
54 observational study
55 part
56 patients
57 reduction
58 regression
59 retrospective observational analysis
60 retrospective observational study
61 significant benefits
62 significant reduction
63 standard care
64 study
65 subgroup analysis
66 subjects
67 subsequent changes
68 system
69 therapy
70 type 1
71 type 2
72 types
73 schema:name Improving HbA1c Control in Type 1 or Type 2 Diabetes Using Flash Glucose Monitoring: A Retrospective Observational Analysis in Two German Centres
74 schema:pagination 363-372
75 schema:productId N267926c5df944fb29b88fe3fd2d420d5
76 N35c766c0d96f4bc6ae82258300f77e44
77 Nf589cdb2fa7d43efbd4f6fd86f537963
78 schema:sameAs https://app.dimensions.ai/details/publication/pub.1133442360
79 https://doi.org/10.1007/s13300-020-00978-9
80 schema:sdDatePublished 2022-10-01T06:48
81 schema:sdLicense https://scigraph.springernature.com/explorer/license/
82 schema:sdPublisher N59a7780800d5435c83bafd6ac4f28464
83 schema:url https://doi.org/10.1007/s13300-020-00978-9
84 sgo:license sg:explorer/license/
85 sgo:sdDataset articles
86 rdf:type schema:ScholarlyArticle
87 N0226064c6c33441a88e74ebd4fdc9646 rdf:first sg:person.015373573342.27
88 rdf:rest rdf:nil
89 N0eb04d85dadc4afd9ff4553719c0a5c4 schema:issueNumber 1
90 rdf:type schema:PublicationIssue
91 N2326bdfca0034c2a87ff3892a3b97131 rdf:first N59064225e01244bda72fd73f17c7e870
92 rdf:rest N8a51f5d808ce4dd1b06b6e96d6b5c5c2
93 N267926c5df944fb29b88fe3fd2d420d5 schema:name doi
94 schema:value 10.1007/s13300-020-00978-9
95 rdf:type schema:PropertyValue
96 N35c766c0d96f4bc6ae82258300f77e44 schema:name dimensions_id
97 schema:value pub.1133442360
98 rdf:type schema:PropertyValue
99 N5228da9638e1431fb73ce51141eb8dd0 schema:volumeNumber 12
100 rdf:type schema:PublicationVolume
101 N59064225e01244bda72fd73f17c7e870 schema:affiliation grid-institutes:None
102 schema:familyName Rose
103 schema:givenName Ludger
104 rdf:type schema:Person
105 N59a7780800d5435c83bafd6ac4f28464 schema:name Springer Nature - SN SciGraph project
106 rdf:type schema:Organization
107 N8a51f5d808ce4dd1b06b6e96d6b5c5c2 rdf:first sg:person.013245653415.25
108 rdf:rest N0226064c6c33441a88e74ebd4fdc9646
109 Nf589cdb2fa7d43efbd4f6fd86f537963 schema:name pubmed_id
110 schema:value 33314006
111 rdf:type schema:PropertyValue
112 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
113 schema:name Medical and Health Sciences
114 rdf:type schema:DefinedTerm
115 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
116 schema:name Clinical Sciences
117 rdf:type schema:DefinedTerm
118 sg:journal.1044057 schema:issn 1869-6953
119 1869-6961
120 schema:name Diabetes Therapy
121 schema:publisher Springer Nature
122 rdf:type schema:Periodical
123 sg:person.013245653415.25 schema:affiliation grid-institutes:None
124 schema:familyName Klausmann
125 schema:givenName Gerhard
126 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013245653415.25
127 rdf:type schema:Person
128 sg:person.015373573342.27 schema:affiliation grid-institutes:None
129 schema:familyName Seibold
130 schema:givenName Alexander
131 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015373573342.27
132 rdf:type schema:Person
133 sg:pub.10.1007/s00125-012-2708-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036534764
134 https://doi.org/10.1007/s00125-012-2708-9
135 rdf:type schema:CreativeWork
136 sg:pub.10.1007/s00125-019-4894-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1116997264
137 https://doi.org/10.1007/s00125-019-4894-1
138 rdf:type schema:CreativeWork
139 sg:pub.10.1007/s13300-016-0223-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024814077
140 https://doi.org/10.1007/s13300-016-0223-6
141 rdf:type schema:CreativeWork
142 sg:pub.10.1007/s13300-019-00720-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122231011
143 https://doi.org/10.1007/s13300-019-00720-0
144 rdf:type schema:CreativeWork
145 sg:pub.10.1007/s13300-019-00741-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1123313019
146 https://doi.org/10.1007/s13300-019-00741-9
147 rdf:type schema:CreativeWork
148 grid-institutes:None schema:alternateName Abbott Diabetes Care, Wiesbaden, Germany
149 Gemeinschaftspraxis Drs. Klausmann, Aschaffenburg, Germany
150 Zentrum für Diabetes und Gefäßerkrankungen Münster, Munster, Germany
151 schema:name Abbott Diabetes Care, Wiesbaden, Germany
152 Gemeinschaftspraxis Drs. Klausmann, Aschaffenburg, Germany
153 Zentrum für Diabetes und Gefäßerkrankungen Münster, Munster, Germany
154 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...